Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: The effects of ZCCHC10 on alternative splicing in acute myeloid leukemia

PROVIDER: PRJNA1002811 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25545095_subreads.fastq.gz	Fastqsanger.gz
	SRR25545096_subreads.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Homo sapiens

Project description:Global alternative splicing in patients with acute myeloid leukemia

| PRJNA921731 | ENA

Homo sapiens

Project description:Global mRNA alternative splicing in patients with acute myeloid leukemia

| PRJNA924552 | ENA

Homo sapiens

Project description:Genome-wide analysis of alternative splicing points to novel leukemia-relevant genes in acute myeloid leukemia.

| PRJNA126151 | ENA

THP1 immunopeptidogenomics data

Project description:Acute myeloid leukemia cell line THP1 immunopeptidome HLA A2 specific

2021-02-22 | MSV000086922 | MassIVE

RNA sequencing of human, IDH2-mutated, acute myeloid leukemia samples from patients before or during treatment with Enasidenib

Project description:Mutations in isocitrate dehydrogenase 2 (IDH2) occur in many cancers including Acute Myeloid Leukemia (AML). Recently, we showed that single agent Enasidenib, a first-in-class, selective mutant IDH2 inhibitor, produces a 40% response in relapsed/refractory AML patients by promoting differentiation of leukaemic cells. In this current study, we describe two patients who responded to Enasidenib treatment but subsequently relapsed with an IDH2-mutant subclone which had acquired mutations in DHX15 and DDX1 genes. These genes have putative functions in regulating splicing. We have studied the alternative splicing events using RNASeq in the sample pre-relapse (before acquisition of DHX15 and DDX1 mutations) and at relapse (after acquisition of DHX15 and DDX1 mutations).

2018-08-08 | E-MTAB-6660 | biostudies-arrayexpress

Analysis of m6A levels in K562 treted with the FTO inhibitor FB23-3 by m6A-mRNA&lncRNA Epitranscriptomic Microarray

Project description:FTO, an N6-methyladenosine demethylase, has emerged as a promising target for the treatment of specific acute myeloid leukemia (AML) subtypes. Here, we investigate the antiproliferative effects of the FTO inhibitor FB23-2 in leukemia. We demonstrate that FB23-2 potently inhibits proliferation across both AML and CML cell lines, irrespective of their responsiveness to FTO depletion. Interestingly, FB23-2 induces cell cycle arrest without a concurrent increase in m6A levels, suggesting an alternative mechanism of action.

2024-12-26 | GSE254577 | GEO

Post-translational regulation of the exon skipping machinery controls aberrant splicing in T cell leukemia [Jurkat_shSRSF6]

Project description:In this study, we show that pediatric T-cell acute lymphoblastic leukemia (T-ALL) has an alternative mechanism for aberrant splicing that involves post-translational regulation of the splicing machinery via deubiquitination.

2020-06-01 | GSE139621 | GEO

Post-translational regulation of the exon skipping machinery controls aberrant splicing in T cell leukemia [CUTLL1_P5091]

2020-06-01 | GSE139620 | GEO

Post-translational regulation of the exon skipping machinery controls aberrant splicing in T cell leukemia [Jurkat_P5091]

2020-06-01 | GSE139619 | GEO

Post-translational regulation of the exon skipping machinery controls aberrant splicing in T cell leukemia [Jurkat_H3B-8800 6hr]

2020-06-01 | GSE139617 | GEO